23 completed, 16 recruiting, 7 active not recruiting, 7 terminated. 38 Phase 1, 29 Phase 2, 5 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow sotorasib: new trials by email Literature Review of sotorasib trials Research Report on sotorasib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer Adagrasib, Biospecimen Collection, Computed Tomography - Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 29 | 2026-10-15 | 2026-09-02 |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 37 | 2026-06-17 | 2026-09-04 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer SOC (Standard of care), Bevacizumab, Cetuximab - Dynamic Tumor Resistance, Metastatic Colorectal Cancer | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 100 | 2026-04-22 | 2026-10-14 |
| A 2-part Phase 1/2 Open-label Trial on ODM-212 ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel - Mesothelioma, Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Orion Corporation, Orion Pharma | 229 | 2026-03-27 | 2026-11-05 |
| A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation Sotorasib, Panitumumab - Advanced Solid Tumors | Phase 2 | Recruiting | Amgen | 14 | 2026-01-02 | 2026-07-23 |
| 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab Administration of experimental treatment association (sotorasib, panitumumab 5FU) - Colorectal Carcinoma, KRAS G12C Mutation | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 300 | 2025-08-31 | 2025-08-15 |
| Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients Sotorasib - Non-Small Cell Lung Cancer | Completed | Amgen | 102 | 2025-08-11 | 2026-04-07 | |
| Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) - Pancreatic Adenocarcinoma | Phase 1 | Recruiting | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 15 | 2025-08-08 | 2026-04-30 |
| AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC Sotorasib, Lenvatinib - Metastatic Non Small Cell Lung Cancer, KRAS G12C | Phase 2 | Withdrawn | ETOP IBCSG Partners Foundation | 2025-03-01 | 2024-11-20 | |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors VVD-159642, Sotorasib, Trametinib - Advanced Solid Tumors | Phase 1 | Recruiting | Vividion Therapeutics, Inc. | 220 | 2025-02-25 | 2026-03-18 |
| A Study of Sotorasib in People With Brain Tumors Sotorasib - Brain Tumor | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2025-01-29 | 2026-05-22 |
| A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Divarasib, Sotorasib, Adagrasib - Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 338 | 2024-09-23 | 2026-09-16 |
| Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). Anvumetostat, Carboplatin, Paclitaxel - Thoracic Tumors, Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Amgen | 49 | 2024-09-17 | 2026-05-28 |
| A Study of Sotorasib in People With Non-Small Cell Lung Cancer Sotorasib - Non Small Lung Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 39 | 2024-08-30 | 2026-09-11 |
| ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer Alectinib, Brigatinib, Lorlatinib 100 mg - NSCLC Stage IV, Sex Disorder | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 80 | 2024-08-05 | 2024-08-09 | |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 105 | 2024-08-01 | 2026-10-22 |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation FOLFIRI Regimen, Sotorasib, Panitumumab - Metastatic Colorectal Cancer | Phase 3 | Recruiting | Amgen | 450 | 2024-07-17 | 2026-09-03 |
| A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants Sotorasib - Healthy Participants | Phase 1 | Withdrawn | Amgen | 2024-07-15 | 2024-04-12 | |
| Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer Biopsy, Biospecimen Collection, Carfilzomib - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2024-04-24 | 2026-04-03 |
| Ladarixin With Sotorasib in Advanced NSCLC - Phase II Sotorasib, Ladarixin - Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation | Phase 2 | Withdrawn | NYU Langone Health | 2024-04-01 | 2024-03-29 |
Showing 20 of 68. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (27) · Lung Neoplasms (12) · Colorectal Neoplasms (5) · Neoplasms (5) · Neoplasm Metastasis (4) · Pancreatic Neoplasms (2) · Adenocarcinoma of Lung (1) · Brain Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Endometrial Neoplasms (1) · Erectile Dysfunction (1) · Eunuchism (1) · Fallopian Tube Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Amgen (27) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · NYU Langone Health (2) · Allist Pharmaceuticals, Inc. (1) · City of Hope Medical Center (1) · Criterium, Inc. (1) · Deciphera Pharmaceuticals, LLC (1) · Devalingam Mahalingam (1) · ETOP IBCSG Partners Foundation (1) · Effector Therapeutics (1) · Erasca, Inc. (1) · Federation Francophone de Cancerologie Digestive (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)
United States (52) · Spain (17) · France (16) · Italy (14) · Germany (13) · Australia (12) · South Korea (11) · Taiwan (11) · Netherlands (10) · Belgium (9) · Greece (9) · Japan (9) · United Kingdom (9) · Canada (8) · Austria (7)
Salman Punekar, MD (2) · Alfredo Addeo (1) · Andreas N Saltos (1) · Byoung Chul Cho (1) · Devalingam Mahalingam, MD (1) · Douglas Warner, MD (1) · Ferdinandos Skoulidis, MD,PHD (1) · Filippo Pietrantonio, MD (1) · Grace K Dy (1) · Gregory Riely, MD, PhD (1) · Hossein Borghaei, DO (1) · James M Ford (1)
PMID 39604046, PMID 31820981, PMID 36546651, PMID 36764316, PMID 39752885, PMID 39777405, PMID 40333694, PMID 42814800
2023 (2), U10CA180820 (2), 2025 (1), P30CA033572 (1), U10CA180888 (1), UM1CA186644 (1)